Abstract: The present invention relates to a plant extract for treating diabetes and a process for making same. The plant extract of the invention is prepared from an overground part of Hedychium coronarium Koenig, which has the efficacies of lowering blood glucose, increasing insulin levels, reducing insulin resistance and treating and/or preventing diabetes without overly reducing blood glucose in a subject, i.e., not reducing blood glucose in a fasting subject. Also provided herein is a method for treating diabetes in a subject in need thereof comprising administering an effective amount of the plant extract to the subject.

Abstract: The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.

Abstract: The present invention provides a pharmaceutical composition for treating skin disorders, including enhancing the healing of wounds for diabetic patients. Specifically, this invention relates to the use of the extracts of Plectranthus amboinicus and Centella asiatica for improving skin disorders, including enhancing the healing of wounds for diabetic patients, and a pharmaceutical composition comprising the extracts of Plectranthus amboinicus and Centella asiatica as well as a wound dressing comprising the same. The invention also provides a method for preparing the crude extract and extract of Plectranthus amboinicus.

Abstract: A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.

Abstract: Compounds represented by the formula (I) or pharmaceutically acceptable salts thereof: R2—Y—Z-Q-A-R1??Formula (I) wherein R1, R2, Y, Z, Q, and A are as defined. These compounds are inhibitors of tubulin polymerization by binding at colchicines binding site and are useful in the treatment of tumors or mitotic diseases such as cancers, gout, and other conditions associated with abnormal cell proliferation.

Abstract: This invention relates to methods for treatment of nephritis. This invention further provides a method of treating with nephritis comprising administering to the subject an amount of herbal pharmaceutical composition thereof effective to treat the subject. Move particularly, this invention provides an herbal pharmaceutical composition comprising Rhizoma Atractylodis macrocephalae, Eucommiae cortex, Lonicerae caulis, and Hedyotidis diffusae Herba thereof for use in treating a subject afflicted with active nephritis.

Abstract: This invention relates to a mutant E. coli heat-labile enterotoxin (LT) subunit A that can be used as an adjuvant. This subunit A mutant contains an amino acid substitution at a position corresponding to position 61 of a wild-type LT. An LT containing this mutated subunit A exhibits reduced toxicity compared to its wild type counterpart.

Abstract: This invention relates to a mutant E. coli heat-labile enterotoxin (LT) subunit A that can be used as an adjuvant. This subunit A mutant contains an amino acid substitution at a position corresponding to position 61 of a wild-type LT. An LT containing this mutated subunit A exhibits reduced toxicity compared to its wild type counterpart.

Abstract: An aqueous inhalation pharmaceutical composition comprising a polypeptide or protein is provided. The composition of the present invention can improve the bioavailability of the polypeptide and protein, and avoid inducing toxicity in the lung.

Abstract: A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.

Abstract: The present invention is related to the use of an overground part of Hedychium coronarium Koenig in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes without overly reducing blood glucose in a subject; i.e., not reducing blood glucose in a fasting subject. The present invention also relates to an extract and composition of the overground part of Hedychium coronarium Koenig and its use in lowering blood glucose, increasing insulin levels and treating and/or preventing diabetes.

Abstract: The present invention provides a pharmaceutical composition for treating skin disorders, including enhancing the healing of wounds for diabetic patients. Specifically, this invention relates to the use of the extracts of Plectranthus amboinicus and Centella asiatica for improving skin disorders, including enhancing the healing of wounds for diabetic patients, and a pharmaceutical composition comprising the extracts of Plectranthus amboinicus and Centella asiatica as well as a wound dressing comprising the same. The invention also provides a method for preparing the crude extract and extract of Plectranthus amboinicus.

Abstract: Indolinone compounds of formula (I) or (II): wherein A, R1, R2, R3, R4, R5, R6, R7, and n are defined herein. Also disclosed are methods for decreasing the activity of a protein kinase and for treating a protein kinase-related disease, such as cancer, with these compounds.

Abstract: The present invention relates to a Polygonum multiflorum extract and the preparation process thereof. The Polygonum multiflorum extract of the present invention mainly comprises 2,3,5,4?-tetrahydroxystilbene-2-O-?-D-glucoside and catechin. The present invention also relates to the use of the Polygonum multiflorum extract of the present invention for the treatment or prevention of dementia.

Abstract: The main goals of the invention are to develop the long-term release of Granisetron injection implant composition with biodegradable polymer and to develop relative processing. Granisetron is mixed with different biodegradable polymers, and then hot melt extrusion technique with different diameter, temperature, rate of extrusion and holding time is applied to make implant. In vitro dissolution of the Granisetron injection implant composition shows the component continued release of the drug for over 7 days.

Abstract: The present invention relates to a Polygonum multiflorum extract and the preparation process thereof. The Polygonum multiflorum extract of the present invention mainly comprises 2,3,5,4?-tetrahydroxystilbene-2-O-?-D-glucoside and catechin. The present invention also relates to the use of the Polygonum multiflorum extract of the present invention for the treatment or prevention of dementia.

Abstract: A device for detecting methanol concentration in an alcohol-containing solution is disclosed. The device implements an electrochemical bio-detector based on a two-enzyme system to quickly, easily and accurately measure methanol concentration in an alcohol-containing solution at a relatively low cost. A method for detecting methanol concentration in a sample using the same device is also disclosed.

Abstract: A pharmaceutical composition comprising a crude extract or extract of Plectranthus Amboinicus (Lour.) Spreng (PA) for the treatment of rheumatoid arthritis is described. The use of the crude extract or extract of Plectranthus Amboinicus (Lour.) Spreng for the manufacture of medicaments for treating rheumatoid arthritis is also described.

Abstract: The present invention provides a process for the preparation of Plectranthus amboinicus extracts using a stirring separation method. The present invention also relates to a pharmaceutical composition comprising the Plectranthus amboinicus crude extract and/or extract for treating skin disorders, including enhancing the healing of wounds, especially in diabetic patients.

Abstract: Provided is an antibody against enterovirus 71 comprising the amino acid sequence shown in SEQ ID NOS: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 or functionally active homologues thereof. Also provided are methods for obtaining the antibody comprising (a) selecting a yeast expressing such an antibody from a yeast library, (b) culturing the yeast under conditions that the antibody is expressed, and (c) recovering the antibody from the culture. Also provided is a process for producing the antibody comprising (a) culturing a host cell under conditions that the antibody is expressed, (b) recovering the antibody from the culture, wherein the host cells are transformed or transfected for expressing the antibody against enterovirus 71. Also provided are pharmaceutical compositions comprising an antibody against enterovirus 71 and a pharmaceutically acceptable carrier or diluent, wherein the antibody has an anti-virus agent or detectable label attached thereto.